EXPERIMENTAL STUDY

**Follistatin-related gene expression, but not follistatin expression, is decreased in human endometrial adenocarcinoma**

Pasquapina Ciarmela, Pasquale Florio, Matthildur Sigurðardóttir, Paolo Toti¹, Veronique Maguer-Satta², Ruth Rimokh², Aldo Altomare, Piero Tosi¹ and Felice Petraglia

Chair of Obstetrics and Gynecology, Department of Pediatrics, Obstetrics and Reproductive Medicine, and ¹Department of Human Pathology and Oncology, University of Siena, Siena, Italy, and ²INSERM U453, Centre Leon Berard, 69373 Lyon, France

(Correspondence should be addressed to F Petraglia, Chair of Obstetrics and Gynecology, Department of Pediatrics, Obstetrics and Reproductive Medicine, University of Siena, Policlinico ‘Le Scotte’, viale Bracci, 53100 Siena, Italy; Email: petraglia@unisi.it)

P Ciarmela and P Florio contributed equally to this work

**Abstract**

**Objective**: Activin A is a multifunctional growth and cell differentiation factor produced by normal endometrium, and secreted in high amounts by endometrial adenocarcinoma. In the present study we evaluated the expression of two inhibitory activin A ligands, follistatin and follistatin-related gene (FLRG), in endometrial adenocarcinoma and in age-matched healthy human endometrium.

**Design and methods**: Atropic menopausal (n = 13) and tumoral (n = 9 adenocarcinoma) tissues were processed to evaluate mRNA expression levels (by semiquantitative RT-PCR) and peptide localization (by immunohistochemistry). Differences were evaluated by the unpaired t-test and assumed to be statistically significant when P < 0.05.

**Results**: Both control and tumoral endometrial samples express and localize follistatin and FLRG. However, whereas follistatin mRNA expression did not differ significantly, FLRG was significantly lower in endometrial adenocarcinoma than in healthy endometrial specimens (P < 0.0001). With respect to the localization of proteins, follistatin was immunolocalized in endometrial epithelial and vascular cells both in tumoral and healthy endometrium without any significant difference in intensity. Nuclear and cytoplasmic FLRG immunolocalization was seen in glands, and only nuclear immunolocalization was found in stroma and vessels of healthy endometrium. FLRG was weakly immunostained in endometrial adenocarcinoma.

**Conclusions**: Whilst follistatin expression is unchanged, FLRG is down-regulated in endometrial adenocarcinoma. As activin A is a differentiation factor of human endometrium, the present findings support an imbalance between increased activin A and decreased FLRG expression in endometrial cancer, so that the failure of the activin A pathway through FLRG may be pivotal in endometrial tumorigenesis.

*European Journal of Endocrinology* **151** 251–257

**Introduction**

Activin A is a dimeric protein (composed of two βA subunits) member of the transforming growth factor-β superfamily, a group of structurally similar but functionally diverse growth factors (1). Despite being initially isolated from porcine ovarian follicular fluid, activin A subunits have subsequently been found in a host of organs where, acting on its own receptors (ActRs), it exerts a wide variety of effects depending upon the cell system examined; however, it acts mainly as a local modulator of cell growth and differentiation (2).

Follistatin is a monomeric glycoprotein that, despite being structurally unrelated to activins, is able to bind activin A with high affinity, preventing interaction to its own receptors, and thus neutralizing its biological effects (2–9). Recently, a new protein that shares the characteristic 10-cysteine structures of follistatin domains was cloned from a B cell leukemia line based on its overexpression in response to a chromosomal translocation (10). Referred to as follistatin-related gene (FLRG) on the basis of the striking sequence homology with follistatin (11), it also shares a similar N-terminal domain with follistatin, a region that is crucial for the binding to activin (12) and, like follistatin, it binds strongly to activin (11, 13, 14).

Activin A, follistatin (15–22) and FLRG (23) are expressed by human endometrium, and human
endometrial cells are also able to secrete activin A and follistatin in the uterine washing fluid throughout the menstrual cycle (22). Furthermore, activin A mRNA and protein expression have been reported to be significantly increased in endometrial adenocarcinoma (21), as well as in the serum and uterine washing fluid of patients affected by endometrial cancer (15).

Since no data are available on follistatin and FLRG in endometrial cancer, in the present study we investigated the mRNA expression levels and peptides distribution in endometrial adenocarcinoma compared with healthy age-matched controls.

Materials and methods

Informed written consent was obtained from all patients prior to inclusion in the study, for which approval from the local Human Investigation Committee was obtained.

Two groups of women were studied. The first group consisted of post-menopausal women with endometrial adenocarcinoma (n = 9; age range 61–79 years), who enrolled at the time of diagnosis, and had not taken any hormonal replacement therapy in their clinical history. Pathological diagnosis was carried out on hysterectomy specimens and, according to the criteria of the International Federation of Gynecology and Obstetrics, they were classified as well differentiated (grade 1; n = 6 endometrioid adenocarcinoma, of whom n = 1 had squamous differentiation and n = 1 clear cell carcinoma) and poorly differentiated (grade 3; n = 3 endometrioid adenocarcinoma) (Table 1). The second group consisted of atrophic post-menopausal women (n = 13; age range 64–78 years), who underwent hysterectomy for uterine prolapse (controls), and served as age-matched controls. In the clinical history of these subjects, the absence of infections or neoplastic diseases, and of any estrogen and/or progestin pretreatment were the exclusion criteria.

All specimens collected were, in part, fixed by immersion in 10% buffered formalin for the immunohistochemistry study, and, in part, immediately submerged in an RNA stabilization reagent (RNAlater, QIAGEN, Milan, Italy) for the extraction of total RNA, in order to perform qualitative and semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR).

RNA preparation

Samples were disrupted and homogenized using Mixer Mill MM 300 (QIAGEN) and total RNA was extracted with RNeasy Protect Mini Kit and treated with RNase-free DNase according to the manufacturer’s instructions (QIAGEN). Total RNA was quantified by UV absorption at 260 nm.

RT-PCR

The reverse transcription reaction was carried out using a Thermoscript RT-PCR system purchased from Invitrogen (Milan, Italy). First-strand cDNA was synthesized from 1 µg total RNA. After denaturing template RNA, oligo d(T) primers, and 10 mmol/l dNTP mix for 5 min at 65 °C, 15 U RT were added in the presence of cDNA synthesis buffer (250 mmol/l Tris acetate (pH 8.4), 375 mmol/l potassium acetate, 40 mmol/l stabilizer), 40 U RNAse inhibitor, 0.1 mol/l dithiothreitol, and diethyl pyrocarbonate (DEPC)-treated water to make 20 µl. The mixture was incubated at 50 °C for 5 min to stop the reaction and stored at −20 °C. Two microliters of the product were used for the PCR reaction.

Table 1 Individual intensity of follistatin and FLRG immunostaining of atropic (controls) and endometrioid cancer tissues scored on a subjective scale ranging from – (no staining) to +++ (maximal staining) by three independent assessors.

<table>
<thead>
<tr>
<th>Follistatin</th>
<th>FLRG</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Controls</strong></td>
<td><strong>Staining intensity</strong></td>
</tr>
<tr>
<td>#1</td>
<td>++</td>
</tr>
<tr>
<td>#2</td>
<td>++</td>
</tr>
<tr>
<td>#3</td>
<td>++</td>
</tr>
<tr>
<td>#4</td>
<td>+</td>
</tr>
<tr>
<td>#5</td>
<td>++</td>
</tr>
<tr>
<td>#6</td>
<td>++</td>
</tr>
<tr>
<td>#7</td>
<td>++</td>
</tr>
<tr>
<td>#8</td>
<td>+</td>
</tr>
<tr>
<td>#9</td>
<td>+</td>
</tr>
<tr>
<td>#10</td>
<td>+</td>
</tr>
<tr>
<td>#11</td>
<td>+</td>
</tr>
<tr>
<td>#12</td>
<td>++</td>
</tr>
<tr>
<td>#13</td>
<td>+</td>
</tr>
</tbody>
</table>

* With squamous differentiation; **Clear cell endometrioid adenocarcinoma.
The polymerase chain reaction was performed under the following conditions: 20 mmol/l Tris–HCl, pH 8.4, 50 mmol/l KCl, 1.5 mmol/l MgCl2, 0.25 mmol/l of each dNTP, 1 U Taq DNA polymerase, recombinant 0.4 μmol/l (final concentration) primers (Invitrogen) in 50 μl of total volume. The specific primers used to amplify cDNA fragments corresponding to follistatin (Genebank accession no. J03771), common to both splice variants, FLRG (Genebank accession no. U76702) and hypoxanthine phosphoribosyltransferase (HPRT (Genebank accession no. M26434), used as a housekeeping gene (24)), were: 5’TGCACCTGAGAAGA- GGCTAC3 (sense) and 5’ACAGAAGGCTCATTCC- GACT3 (antisense) for follistatin (included intron size: 904 bp; expected size: 201 bp); 5’ACCTGAGGCTCATGT- ACCG3 (sense) and 5’TGTGAGGAGATGAG3 (antisense) for FLRG (included intron size: 792 bp; expected size: 198 bp); 5’TGAAGCTGCAGACACT- CAGG3 (sense) and 5’CTCTCCAAACACCATCACCT3 (antisense) for HPRT (included intron size: 270 bp; expected size: 99 bp). The primers for follistatin and FLRG, as well as those for HPRT, both span large introns, reducing the likelihood of possible genomic material amplification thus serving to detect possible genomic contamination. Computer analysis performed to compare the synthesized oligomers with the human sequences in the gene database of the National Center for Biotechnology (NCBI), using BLAST (25), revealed no significant homology with other genes.

PCRs for follistatin consisted of 32 thermal cycles of 94°C for 30 s, 50°C for 1 min and 72°C for 20 s. For FLRG, 36 thermal cycles of 94°C for 30 s, 55°C for 1 min and 72°C for 20 s were used. The HPRT program was 30 thermal cycles of 94°C for 30 s, 52°C for 30 s and 72°C for 12 s. The first cycle was preceeded by denaturation at 94°C for 2 min, and the last cycle was followed by an extension at 72°C for 5 min. The number of PCR cycles was established after testing a range of 20–40 to ensure that the amount of DNA product remained in the logarithmic range of the amplification curve, so that useful semi-quantified comparisons could be made. For each reaction, the reverse transcriptase was omitted in the amplification comparisons could be made. For each reaction, the cation curve, so that useful semi-quantified

Range 20 –40 to ensure that the amount of DNA pro-

duct remained in the logarithmic range of the amplifi-

cation curve, so that useful semi-quantified

quired under UV light. The expected bands

Photographed under UV light. The expected bands

5-methylthiouracil and tumoral patients, whereas the relative abundance

expression did not differ between healthy subjects

and no amplified fragment caused by DNA contami-

nation was detected in any experiment (data not

shown).

As shown graphically in Fig. 1, follistatin mRNA

expression did not differ between healthy subjects

and tumoral patients, whereas the relative abundance

of FLRG mRNA with respect to HPRT was signifi-

cantly decreased in endometrial adenocarcinoma

(P < 0.0001).

Localization of follistatin peptide

Post-menopausal endometrial glands, stromal and endothelial cells were positively stained by follistatin (Fig. 2F and 2G). Follistatin immunostaining was also found in endometrial adenocarcinoma cells (glands and stroma), intramyometrial and intratumoral
neoformed vessels, smooth muscle cells of the media in muscular arteries, and in endothelial cells of arteries, veins and capillaries (Fig. 2A to 2E). No significant difference in stain intensity was observed between healthy and tumoral endometrium (Table 1).

**Localization of FLRG peptide**

In normal post-menopausal endometrium, glandular epithelial cells were strongly and consistently immunoreactive for FLRG, both in the cytoplasm and the nucleus, while in stromal cells immunoreactivity was restricted to the nucleus. Cytoplasmic and nuclear FLRG staining was also found in both endothelial and smooth muscle cells of the vessels (Fig. 3F).

Neoplastic glands (Fig. 3A to 3E) featured positive immunoreactivity both in the nucleus and the cytoplasm, but the stain was very weak when compared with vessel wall and non-neoplastic glandular cells (entrapped in the same slide), which conversely were intensively stained. In some areas, tumoral cells were so devoid of FLRG staining to be considered as negative (Fig. 3A to 3E). This result was present in all the different samples of endometrial adenocarcinoma evaluated, independent of the grade of differentiation.

With respect to healthy samples, the staining intensity was found to be lower by all independent assessors (Table 1).

**Discussion**

In the present study we first demonstrated that human post-menopausal endometrium expresses both FLRG and follistatin mRNAs and peptides, and that they are mainly localized in glandular, stromal and endothelial cells. This localization resembles that previously reported in fertile women, thus suggesting that the localization of the two activin A binding proteins does not differ between fertile and menopausal endometrium (22, 23). Furthermore, in menopausal endometrium FLRG was detected not only in the cytoplasm, but also in the nucleus of all positive cells, confirming the evidence found in fertile women (23). Since the nuclear localization signal has previously been described for the activin βA-subunit precursor, and activin A has been observed in the nuclei of rat spermatogenic cells (27), we conclude that FLRG may bind activin A en route to the nucleus, or that some novel transport mechanisms may be involved in activin A signaling, both in normal and in tumoral endometrium.

In addition, FLRG immunostaining was very weak in endometrial tumoral glands, whilst it remained very intense in vascular vessels, supporting its role in tumoral angiogenesis. Because activin A modulates endothelial cell functions (28, 29) it is possible that there is a role for FLRG in modulating the activin A effect on vascular proliferation and angiogenesis.

The second result of the present study is that the expression of FLRG, but not of follistatin, is decreased in endometrial cancer, questioning the role played by the activin A pathway in endometrial carcinoma. In fact, we (15) and others (21) have reported that activin A is over-expressed and secreted by tumoral endometrium, thus suggesting that activin A signaling may be involved in the events cascade leading to carcinomaogenesis. This concept is further reinforced by the fact that activin A is able to modulate the differentiation of both healthy (18) and tumoral (30) endometrial cells, as it stimulates stromal cells to differentiate in decidual cells, and because the loss of activin A signaling has been related to the malignant progression of an estrogen receptor-negative endometrial cancer cell line (30).
The lack of changes in follistatin expression is also surprising, since in other tissues its expression, like that of FLRG, is up-regulated by activin A and providing a negative feed-back on activin A actions (31).

Taken together, these findings lead us to suggest that activin A signal in human endometrial cancer may be impaired through changes in local FLRG and follistatin expression. Thus, the specific misregulation of FLRG/follistatin expression in these tumors may indicate: (i) a functional separation of activin signaling based on the FLRG and follistatin expression; (ii) that a molecular component of the activin signaling pathway that is unique to the regulation of FLRG may be missing in endometrial tumors; and (iii) that the missing portion of the activin signaling pathway that fails to increase follistatin transcription is also a candidate for the lesion that fails to bring about robust activin-mediated inhibition of cell proliferation, and therefore may contribute to endometrial tumor progression.

**Figure 2** Follistatin immunolocalization. (A–C) Well-differentiated endometrioid adenocarcinoma showing cytoplasmic immunopositivity for follistatin (solid arrows). Endothelial cells of vessels in the stroma (arrowheads) were also positive. Inside a vein (B), circulating leucocytes (*) were also positive. (D, E) Neoplastic cells of poorly differentiated endometrial adenocarcinoma (E: with squamous differentiation) also showed immunopositivity both in neoplastic (solid arrow) and endothelial cells (arrowheads). The open arrow shows stromal cells. (F) Atrophic post-menopausal endometrial stromal (open arrow) and epithelial cells also featured follistatin positivity. (G) Non-neoplastic endothelial cells (arrowhead). (H) Negative control.
In conclusion the expression of FLRG, but not of follistatin, changes in endometrial adenocarcinoma, suggesting that the failure in a common pathway that involves the regulation of activin may be pivotal in endometrial tumor progression.

**References**


4 Ling N, Ying SY, Ueno N, Esch F, Denoyelle C & Guillemin R. Isolation and partial characterization of a Mr 32,000 protein

**Figure 3** FLRG immunolocalization in well differentiated (A–D) and poorly differentiated (E) endometrioid adenocarcinoma. Neoplastic glands (indicated by the solid arrows) showed weaker and patchy immunoreaction. The vessel walls featured stronger immunoreactivity both in endothelial and smooth muscle cells (arrowheads). Endometrial stromal cells featured immunoreactivity restricted to the nucleus (open arrows). (F) Non-neoplastic post-menopausal endometrial glands (as shown by arrows) presented strong and consistent immunoreaction both in the cytoplasm (solid arrow) and the nucleus (open arrow). Endothelial cells (arrowhead) were also positive. (G) Negative control.
with inhibin activity from porcine follicular fluid. PNAS 1985 82 7217–7221.


Jones RL, Salamonsen LA, Critchley HO, Rogers PA, Alvari N & Findlay JK. Inhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progesterin-only contraception. Molecular Human Reproduction 2000 6 1107–1117.


